Irreversible binding kinetics of neuropeptide y Ligands to Y2 but not to Y1 and Y5 receptors

被引:26
作者
Dautzenberg, FM
Neysari, S
机构
[1] Johnson & Johnson Res & Dev, CNS Res, BE-2340 Beerse, Belgium
[2] F Hoffmann La Roche & Cie AG, Preclin Res, Basel, Switzerland
关键词
Radioligand binding; competition binding; ligand association; ligand dissociation; insurmountable antagonism;
D O I
10.1159/000085897
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Neuropeptide Y (NPY) receptors type 1 (Y-1), type 2 Y-2) and type 5 (Y-5) were tested for their kinetic properties to bind radiolabeled NPY or PYY. Rapid association and dissociation was observed with recombinant (HEK293 cells) and endogenous (SK-N-MC cells) human Y-1 and recombinant mouse Y-5 receptors. Recombinant ( HEK293) and endogenous (SMS-KAN) human Y-2 receptors bound both radiolabels comparable to the Y-1 receptors, but only minimal (similar to 20%) dissociation of both radiolabels was observed after long incubation time (>8 h). Furthermore, neither peptide nor small molecule Y-2 ligands efficiently competed for binding to Y 2 receptors once association binding had been initiated. The Y-2-selective antagonist BIIE0246 behaved as an insurmountable antagonist in functional assays when pre-incubated for 30 min before agonist addition, but was a competitive antagonist when co-applied with the agonist. These data show that Y-2 receptors in contrast to Y-1 and Y-5 receptors bind their ligands in an irreversible manner. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:21 / 29
页数:9
相关论文
共 37 条
[1]
Radioligand binding and functional characterization of recombinant human NmU1 and NmU2 receptors stably expressed in clonal human embryonic kidney-293 cells [J].
Aiyar, N ;
Disa, J ;
Foley, JJ ;
Buckley, PT ;
Wixted, WE ;
Pullen, M ;
Shabon, U ;
Dul, E ;
Szekeres, PG .
PHARMACOLOGY, 2004, 72 (01) :33-41
[2]
Neuropeptide Y (NPY) family of hormones: Progress in the development of receptor selective agonists and antagonists [J].
Balasubramaniam, A .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (15) :1165-1175
[3]
Neuropeptide YY5 receptors inhibit kindling acquisition in rats [J].
Benmaamar, R ;
Richichi, C ;
Gobbi, M ;
Daniels, AJ ;
Beck-Sickinger, AG ;
Vezzani, A .
REGULATORY PEPTIDES, 2005, 125 (1-3) :79-83
[4]
Y-receptor subtypes - How many more? [J].
Blomqvist, AG ;
Herzog, H .
TRENDS IN NEUROSCIENCES, 1997, 20 (07) :294-298
[5]
Characterization of N-(1-acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]-acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide YY2 receptor [J].
Bonaventure, P ;
Nepomuceno, D ;
Mazur, C ;
Lord, B ;
Rudolph, DA ;
Jablonowski, JA ;
Carruthers, NI ;
Lovenberg, TW .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (03) :1130-1137
[6]
Signaling and ligand binding by recombinant neuromedin U receptors:: Evidence for dual coupling to Gαq/11 and Gαi and an irreversible ligand-receptor interaction [J].
Brighton, PJ ;
Szekeres, PG ;
Wise, A ;
Willars, GB .
MOLECULAR PHARMACOLOGY, 2004, 66 (06) :1544-1556
[7]
In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor [J].
Caballero-George, C ;
Vanderheyden, PML ;
Solis, PN ;
Gupta, MP ;
Pieters, L ;
Vauquelin, G ;
Vlietinck, A .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 458 (03) :257-262
[8]
Chiou WJ, 2000, J CARDIOVASC PHARM, V36, pS48, DOI 10.1097/00005344-200036051-00017
[9]
Dautzenberg FM, 1997, J NEUROCHEM, V69, P1640
[10]
Evidence for the abundant expression of arginine 185 containing human CRF2α receptors and the role of position 185 for receptor-ligand selectivity [J].
Dautzenberg, FM ;
Huber, G ;
Higelin, J ;
Py-Lang, G ;
Kilpatrick, GJ .
NEUROPHARMACOLOGY, 2000, 39 (08) :1368-1376